Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samip Patel

Otolaryngology Jacksonville, FL Medical Doctor

NPI 1053575993 CMS profile 1105251

4500 San Pablo Rd S, Jacksonville, FL 32224

Open in the dashboard

General payments

$38,464

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samip Patel of Jacksonville, FL is reported in the CMS Open Payments database as having received $38,464 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,180 18
2024 General $11,073 15
2023 General $396 7
2022 General $2,142 5
2021 General $2,629 3
2020 General $360 5
2019 General $684 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samip Patel
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Samip Patel were reported at $21,180. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Samip Patel Otolaryngology median Middle half National median
2019 $684 $194 $82–$512 $163
2020 $360 $118 $42–$280 $114
2021 $2,629 $167 $63–$444 $132
2022 $2,142 $216 $84–$545 $149
2023 $396 $235 $93–$588 $160
2024 $11,073 $280 $111–$699 $164
2025 $21,180 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $13,545 20 payments
  2. Janssen Research & Development, LLC $9,646 7 payments
  3. Access Pro Medical, LLC $7,500 1 payment
  4. Cook Incorporated $3,880 2 payments
  5. Janssen Scientific Affairs, LLC $900 1 payment
  6. Stryker Corporation $860 8 payments
  7. Janssen Pharmaceuticals, Inc $600 1 payment
  8. Cook Medical LLC $365 6 payments
  9. KLS-Martin L.P. $283 3 payments
  10. Acclarent, Inc $283 4 payments
  11. Other $602 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,265 6 payments
  2. Education $10,051 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,880 2 payments
  4. Food and Beverage $3,658 40 payments
  5. Travel and Lodging $2,610 10 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $13,545 20 payments
  2. Matriderm $7,500 1 payment
  3. Cook-Swartz $3,979 3 payments
  4. VSP SYSTEM, VSP CRANIAL $322 3 payments
  5. PTEYE PARATHYROID DETECTION SYSTEM $216 2 payments
  6. VSP RECONSTRUCTION $205 2 payments
  7. NSE - SONOPET $142 1 payment
  8. RAZADYNE $140 1 payment
  9. NA $129 1 payment
  10. ACCLARENT AERA EUSTACHIAN TUBE BALLOON DILATION SYSTEM $116 1 payment
  11. Other $779 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

41

Median for Otolaryngology: 297

Drug cost

$342

Median for Otolaryngology: $6,314

Branded share of claims

26.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Hcl Viscous Lidocaine Hcl Brand 11 $240
Oxycodone Hcl Generic 15 $74
Levothyroxine Sodium Generic 15 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$187,972

Medicare's payments for the services billed

Medicare patients

256

Average age 74

Services billed

697

89 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 35%
Diabetes 30%
Chronic kidney disease 30%
Atrial fibrillation 23%
COPD 23%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record